IL17A and neoplasm: To further confirm the important role of IL-17A in the BTNL2 blockage, we purified murine IL-17A-Fc recombinant proteins (Fig. 2g, right panel), and found that treatment with recombinant IL-17A-Fc also abolished the anti-tumour effect of BTNL2 blockade (Fig. 2g, left panel).